Lupin Limited, a global pharmaceutical leader, announced the acquisition of the Huminsulin® range from Eli Lilly and Company to enhance its diabetes treatment portfolio in India. The acquisition includes Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, which Lupin had been distributing under existing agreements.
Significance of the Acquisition
- Diabetes Management: The Huminsulin range addresses the growing need for type 1 and type 2 diabetes management in India, where insulin therapy is crucial for controlling blood sugar levels.
- Expanded Portfolio: This move solidifies Lupin’s commitment to providing comprehensive diabetes care by offering a broader range of affordable insulin options.
Statements from Leadership
Nilesh Gupta, Managing Director of Lupin, highlighted the strategic importance of the acquisition:
“This acquisition strengthens our ability to deliver high-quality diabetes care, reinforcing our commitment to combating diabetes and supporting healthier lives.”
Rajeev Sibal, President of India Region Formulations at Lupin, added:
“We are dedicated to providing holistic diabetes care. This acquisition allows us to extend better healthcare solutions to millions of patients.”
About Lupin
Headquartered in Mumbai, Lupin is a global leader in pharmaceuticals, with a strong presence in India and the U.S. The company specializes in branded and generic formulations, biotechnology products, and active pharmaceutical ingredients, serving over 100 markets worldwide.
